Eli Lilly and Company $LLY Shares Bought by Plato Investment Management Ltd

Plato Investment Management Ltd lifted its stake in Eli Lilly and Company (NYSE:LLY) by 6.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 17,492 shares of the company’s stock after acquiring an additional 1,037 shares during the period. Eli Lilly and Company accounts for approximately 1.0% of Plato Investment Management Ltd’s holdings, making the stock its 13th biggest position. Plato Investment Management Ltd’s holdings in Eli Lilly and Company were worth $13,586,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Lazard Freres Gestion S.A.S. increased its stake in Eli Lilly and Company by 114.3% in the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock valued at $60,253,000 after buying an additional 41,222 shares during the period. Precedent Wealth Partners LLC increased its stake in Eli Lilly and Company by 15.3% in the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after buying an additional 39 shares during the period. Capital Advisors Inc. OK increased its stake in Eli Lilly and Company by 6.8% in the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after buying an additional 429 shares during the period. Family CFO Inc acquired a new position in Eli Lilly and Company in the 2nd quarter valued at approximately $54,000. Finally, Duquesne Family Office LLC increased its stake in Eli Lilly and Company by 52.5% in the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after buying an additional 32,640 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $862.96 on Friday. The company’s fifty day moving average is $780.74 and its 200-day moving average is $771.71. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $935.63. The firm has a market cap of $816.76 billion, a price-to-earnings ratio of 56.40, a price-to-earnings-growth ratio of 1.21 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is currently 39.22%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Leerink Partners reiterated a “market perform” rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Berenberg Bank reiterated a “hold” rating and issued a $830.00 price objective (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. JPMorgan Chase & Co. dropped their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, September 16th. HSBC increased their price target on shares of Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Finally, Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $940.00.

Insider Buying and Selling at Eli Lilly and Company

In other news, Director Gabrielle Sulzberger acquired 117 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO David A. Ricks acquired 1,632 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 4,514 shares of company stock worth $2,894,841 in the last quarter. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.